{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:54:58Z","timestamp":1792086898198,"version":"4.4.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1038\/sj.leu.2404565","type":"journal-article","created":{"date-parts":[[2007,2,3]],"date-time":"2007-02-03T03:46:11Z","timestamp":1170474371000},"page":"772-779","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Pharmacologic activation of p53-dependent and p53-independent apoptotic pathways in Hodgkin\/Reed-Sternberg cells"],"prefix":"10.1038","volume":"21","author":[{"given":"M","family":"Janz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"St\u00fchmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L T","family":"Vassilev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R C","family":"Bargou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,2,1]]},"reference":[{"key":"BF2404565_CR1","first-page":"244","volume-title":"World Health Organization classification of tumorsPathology and genetics of tumors of haematopoietic and lymphoid tissues","author":"H Stein","year":"2001","unstructured":"Stein H, Delsol G, Pileri S, Said J, Mann R, Poppema S et al. Classical Hodgkin Lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, (eds). World Health Organization classification of tumorsPathology and genetics of tumors of haematopoietic and lymphoid tissues. IARC Press, Lyon, 2001, 244\u2013253."},{"key":"BF2404565_CR2","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1200\/JCO.2003.07.160","volume":"21","author":"A Josting","year":"2003","unstructured":"Josting A, Wiedenmann S, Franklin J, May M, Sieber M, Wolf J et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003; 21: 3440\u20133446.","journal-title":"J Clin Oncol"},{"key":"BF2404565_CR3","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/01.mph.0000150740.80690.d4","volume":"27","author":"H-MJ Lin","year":"2005","unstructured":"Lin H-MJ, Teitell MA . Second malignancy after treatment of pediatric Hodgkin disease. J Pediatr Hematol Oncol 2005; 27: 28\u201336.","journal-title":"J Pediatr Hematol Oncol"},{"key":"BF2404565_CR4","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1126\/science.1092472","volume":"303","author":"LT Vassilev","year":"2004","unstructured":"Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303: 844\u2013848.","journal-title":"Science"},{"key":"BF2404565_CR5","doi-asserted-by":"publisher","first-page":"3609","DOI":"10.1182\/blood-2005-04-1489","volume":"106","author":"T St\u00fchmer","year":"2005","unstructured":"St\u00fchmer T, Chatterjee M, Hildebrandt M, Herrmann P, Gollasch H, Gerecke C et al. Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood 2005; 106: 3609\u20133617.","journal-title":"Blood"},{"key":"BF2404565_CR6","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1182\/blood-2005-02-0553","volume":"106","author":"K Kojima","year":"2005","unstructured":"Kojima K, Konopleva M, Samudio IJ, Shikami M, Cabreira-Hansen M, McQueen T et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood 2005; 106: 3150\u20133159.","journal-title":"Blood"},{"key":"BF2404565_CR7","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1073\/pnas.0507493103","volume":"103","author":"C Tovar","year":"2006","unstructured":"Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci USA 2006; 103: 1888\u20131893.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF2404565_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/1568009053332627","volume":"5","author":"GL Bond","year":"2005","unstructured":"Bond GL, Hu W, Levine AJ . MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets 2005; 5: 3\u20138.","journal-title":"Curr Cancer Drug Targets"},{"key":"BF2404565_CR9","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/humu.10190","volume":"21","author":"S Peller","year":"2003","unstructured":"Peller S, Rotter V . TP53 in hematological cancer: low incidence of mutations with significant clinical relevance. Hum Mutat 2003; 21: 277\u2013284.","journal-title":"Hum Mutat"},{"key":"BF2404565_CR10","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1046\/j.1365-2141.2001.02566.x","volume":"112","author":"M K\u00fcpper","year":"2001","unstructured":"K\u00fcpper M, Joos S, von Bonin F, Daus H, Pfreundschuh M, Lichter P et al. MDM2 gene amplification and lack of p53 point mutations in Hodgkin and Reed-Sternberg cells: results from single-cell polymerase chain reaction and molecular cytogenetic studies. Br J Haematol 2001; 112: 768\u2013775.","journal-title":"Br J Haematol"},{"key":"BF2404565_CR11","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/ijc.1438","volume":"94","author":"EM Maggio","year":"2001","unstructured":"Maggio EM, Stekelenburg E, Van Den Berg A, Poppema S . TP53 gene mutations in Hodgkin lymphoma are infrequent and not associated with absence of Epstein\u2013Barr virus. Int J Cancer 2001; 94: 60\u201366.","journal-title":"Int J Cancer"},{"key":"BF2404565_CR12","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1182\/blood.V94.5.1755","volume":"94","author":"M Montesinos-Rongen","year":"1999","unstructured":"Montesinos-Rongen M, Roers A, K\u00fcppers R, Rajewsky K, Hansmann M-L . Mutation of the p53 gene is not a typical feature of Hodgkin and Reed\u2013Sternberg cells in Hodgkin's disease. Blood 1999; 94: 1755\u20131760.","journal-title":"Blood"},{"key":"BF2404565_CR13","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1172\/JCI119849","volume":"100","author":"RC Bargou","year":"1997","unstructured":"Bargou RC, Emmerich F, Krappmann D, Bommert K, Mapara MY, Arnold W et al. Constitutive nuclear factor-\u03baB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 1997; 100: 2961\u20132969.","journal-title":"J Clin Invest"},{"key":"BF2404565_CR14","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1182\/blood.V94.9.3129","volume":"94","author":"F Emmerich","year":"1999","unstructured":"Emmerich F, Meiser M, Hummel M, Demel G, Foss H-D, Jundt F et al. Overexpression of I kappa B alpha without inhibition of NF-\u03baB activity and mutations in the I kappa B alpha gene in Reed\u2013Sternberg cells. Blood 1999; 94: 3129\u20133134.","journal-title":"Blood"},{"key":"BF2404565_CR15","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/path.1454","volume":"201","author":"F Emmerich","year":"2003","unstructured":"Emmerich F, Theurich S, Hummel M, Haeffker A, Vry MS, D\u00f6hner K et al. Inactivating I kappa B epsilon mutations in Hodgkin\/Reed\u2013Sternberg cells. J Pathol 2003; 201: 413\u2013420.","journal-title":"J Pathol"},{"key":"BF2404565_CR16","doi-asserted-by":"publisher","first-page":"5378","DOI":"10.1038\/sj.onc.1207705","volume":"23","author":"M Broemer","year":"2004","unstructured":"Broemer M, Krappmann D, Scheidereit C . Requirement of Hsp90 activity for I\u03baB kinase (IKK) biosynthesis and for constitutive and inducible IKK and NF-\u03baB activation. Oncogene 2004; 23: 5378\u20135386.","journal-title":"Oncogene"},{"key":"BF2404565_CR17","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/nrc1716","volume":"5","author":"L Whitesell","year":"2005","unstructured":"Whitesell L, Lindquist SL . HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005; 5: 761\u2013772.","journal-title":"Nat Rev Cancer"},{"key":"BF2404565_CR18","doi-asserted-by":"publisher","first-page":"3712","DOI":"10.1182\/blood-2004-04-1670","volume":"104","author":"M Chatterjee","year":"2004","unstructured":"Chatterjee M, St\u00fchmer T, Herrmann P, Bommert K, D\u00f6rken B, Bargou RC . Combined disruption of both the MEK\/ERK and the IL-6R\/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells. Blood 2004; 104: 3712\u20133721.","journal-title":"Blood"},{"key":"BF2404565_CR19","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1126\/science.1068999","volume":"296","author":"TR Brummelkamp","year":"2002","unstructured":"Brummelkamp TR, Bernards R, Agami R . A system for stable expression of short interfering RNAs in mammalian cells. Science 2002; 296: 550\u2013553.","journal-title":"Science"},{"key":"BF2404565_CR20","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1002\/j.1460-2075.1991.tb04887.x","volume":"10","author":"RJ Harvey","year":"1991","unstructured":"Harvey RJ, Vreugdenhil E, Zaman SH, Bhandal NS, Usherwood PNR, Barnard EA et al. Sequence of a functional invertebrate GABAA receptor subunit which can form a chimeric receptor with a vertebrate \u03b1 subunit. EMBO J 1991; 10: 3239\u20133245.","journal-title":"EMBO J"},{"key":"BF2404565_CR21","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1093\/ajcp\/106.6.728","volume":"106","author":"KS Elenitoba-Johnson","year":"1996","unstructured":"Elenitoba-Johnson KS, Medeiros LJ, Khorsand J, King TC . P53 expression in Reed\u2013Sternberg cells does not correlate with gene mutations in Hodgkin's disease. Am J Clin Pathol 1996; 106: 728\u2013738.","journal-title":"Am J Clin Pathol"},{"key":"BF2404565_CR22","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S0002-9440(10)64876-6","volume":"160","author":"JF Garcia","year":"2002","unstructured":"Garcia JF, Villuendas R, S\u00e1nchez-Beato M, S\u00e1nchez-Aguilera A, S\u00e1nchez L, Prieto I et al. Nucleolar p14ARF overexpression in Reed\u2013Sternberg cells in Hodgkin's lymphoma. Am J Pathol 2002; 160: 569\u2013578.","journal-title":"Am J Pathol"},{"key":"BF2404565_CR23","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1182\/blood-2002-04-1154","volume":"102","author":"S Mathas","year":"2003","unstructured":"Mathas S, Lietz A, Janz M, Hinz M, Jundt F, Scheidereit C et al. Inhibition of NF-\u03baB essentially contributes to arsenic-induced apoptosis. Blood 2003; 102: 1028\u20131034.","journal-title":"Blood"},{"key":"BF2404565_CR24","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1096\/fj.99-1078rev","volume":"14","author":"MV Blagosklonny","year":"2000","unstructured":"Blagosklonny MV . p53 from complexity to simplicity: mutant p53 stabilization, gain-of-function, and dominant-negative effect. FASEB J 2000; 14: 1901\u20131907.","journal-title":"FASEB J"},{"key":"BF2404565_CR25","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1158\/1078-0432.CCR-05-1194","volume":"12","author":"GV Georgakis","year":"2006","unstructured":"Georgakis GV, Li Y, Rassidakis GZ, Martinez-Valdez H, Medeiros LJ, Younes A . Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's Lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death. Clin Cancer Res 2006; 12: 584\u2013590.","journal-title":"Clin Cancer Res"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/2404565.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2404565","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2404565.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T02:40:13Z","timestamp":1648780813000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/2404565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2,1]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["BF2404565"],"URL":"https:\/\/doi.org\/10.1038\/sj.leu.2404565","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,2,1]]},"assertion":[{"value":"13 April 2006","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2006","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2006","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2007","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}